Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Pharmaceuticals: A New Model To De-Risk Drugs

This article was originally published in Start Up

Executive Summary

Christopher Viebacher's new venture Boston Pharmaceuticals was established with enough capital - $600 million - to scour thousands of Phase-I ready programs and build a portfolio of 20 to 25 early-stage drug candidates that it will attempt to de-risk then sell or license to interested partners

Advertisement

Related Content

VC Roundup: Infectious Disease Startup Snags $150m And Former Biogen CEO Scangos
Early Stage Biopharma Financings Kept Up Multibillion-Dollar Pace In 2016
Flagship Ventures Tempts Former Merck CMO With 'Creative' Mentoring Role
Start-Up Quarterly Statistics, Q4 2015
The A-List: The Trend-Shaping Series A Financings Of 2015
Big Rounds, Big Bucks For Biotechs In 2015
Sanofi Board Forces Out CEO Chris Viehbacher Amid Lantus Woes

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC092699

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel